Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Amino Acids

Everolimus

Immunomodulating Agents

Tyrosine Kinase Inhibitors

Sirolimus

Temsirolimus

MTOR Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Immunosuppressive Agents

Immunologic Factors

Tyrosine

Fruquintinib 3mg Qd 21 days on 7 days off; Everolimus 5mg Qd; 28 day cycle until disease progression or intolerable adverse events

Fruquintinib 4mg Qd 21 days on 7 days off; Everolimus 5mg Qd; 28 day cycle until disease progression or intolerable adverse events

Fruquintinib 5mg Qd 21 days on 7 days off; Everolimus 5mg Qd; 28 day cycle until disease progression or intolerable adverse events

Fruquintinib and Everolimus

Zhisong He, M.D

Kaiwei Yang, M.D

Zhisong He, MD

Kaiwei Yang, MD

This study will assess the efficacy and safety profile of fruquintinib in combination with everolimus as second line therapy of clear cell renal cell carcinoma patients who progressed after immunotherapy and tyrosine kinase inhibitor.

This study will assess the efficacy and safety profile of fruquintinib in combination with everolimus as second line therapy of clear cell renal cell carcinoma patients who progressed after immunotherapy and tyrosine kinase inhibitor. Patients will receive fruquintinib 4mgQd/5mgQd 21days on/7 days off plus everolimus 5mg Qd as the dose escalation phase indicates.

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Efficacy and Safety of Fruquintinib in Combination With Everolimus as Second Line Therapy of ccRCC Patients Progressed Post Immunotherapy and Tyrosine Kinase Inhibitors Therapy: a Prospective, Single Arm, Phase II Clinical Trial

the maximum dose in which the proportion of patients who experience dose limited toxicity (DLT) within 28 days after the first dose level is less than or equal to 1/6. When DLT occurs in patients with a dose level greater than 1/6, a dose level lower than this dose level is considered MTD. The MTD dose group requires at least 6 DLT evaluable patients to be confirmed.

Based on the evaluable set of tumor efficacy, it is defined as the sum of the proportions of patients with confirmed complete response (CR) or partial response (PR) as the best overall evaluation per RECIST(Response Evaluation Criteria In Solid Tumors )1.1criteria

The time from when the patient starts receiving the study drug until disease progression (according to RECIST 1.1) or death occurs, whichever occurs first

The best overall assessment is the sum of the proportions of patients who have confirmed CR, PR, and disease stability (SD) (according to RECIST 1.1)

Peking University First Hospital

Spots Global Cancer Trial Database for renal cell carcinoma, clear cell, somatic